TCE: Then and now, and beyond

Please register via https://us06web.zoom.us/webinar/register/WN_Ox85R_yIRQ-Uq6pChy1tRg#/registration

Webinar Title: TCE: Then and now, and beyond

Abstract：

T-cell engagers (TCEs) represent a transformative immunotherapy capable of precisely directing T cells to eliminate diseased cells, having already demonstrated significant efficacy in hematologic malignancies. Currently, TCE development is expanding from hematologic tumors to solid tumors, and from oncology to autoimmune diseases. However, widespread clinical application still faces substantial challenges, including on-target off-tumor toxicity, cytokine release syndrome (CRS), tumor antigen escape, and T-cell exhaustion. Overcoming these hurdles requires enhancing specificity, optimizing molecular design, balancing between anti-tumor potency and safety profile, and developing synergistic combination strategies.

In this frontier field, Dr. Xiaoqiang Kang—Founder, Chairman, and CEO of Leads Biolabs—will discuss the current landscape of TCE development and the challenges the field faces. He will also share his strategic insights on next-generation TCE development and introduce Leads Biolabs' innovative, differentiated platforms: LeadsBody^® and ImBiTDC^TM. Looking ahead, by continuously driving innovation to overcome key bottlenecks, TCE therapies are poised to expand into a much broader spectrum of therapeutic areas.

Speaker Bio:

Xiaoqiang Kang, Founder, Chairman, and CEO of Leads Biolabs. He obtained MS in Hematology from Tongji Medical School, PhD in Biologic Medicine from North Texas University, and was a Postdoc in tumor immunotherapy at the Surgery Branch Chief Dr. Steven Rosenberg’s lab in NCI/NIH. Dr. Kang has over 30 years of experience in the R&D of innovative drugs, particularly in antibody drugs. Dr. Kang previously served as a Principal Scientist and Senior Group Leader at Eli Lilly Pharmaceuticals, and contributed to the development and successful launch of Erbitux^®.